Basic and Clinical Studies of Congenital Urinary Tract Obstruction (R01) | Apply Online

FAQs: NIH Basic and Clinical Studies of Congenital Urinary Tract Obstruction (R01) - PA-07-059

What is the purpose of this NIH funding opportunity?

This NIH opportunity supports research intended to improve the understanding and management of congenital urinary tract obstruction (also described as congenital obstructive uropathy). The announcement emphasizes that congenital obstruction is a major contributor to chronic kidney disease and end-stage renal disease in infants and children, yet the underlying mechanisms and best clinical practices remain uncertain. The FOA aims to generate stronger evidence to reduce disagreements about detection, outcome prediction, and treatment choices.

What is the Funding Opportunity Number (FON) and title?

The Funding Opportunity Number is PA-07-059, and the title is "Basic and Clinical Studies of Congenital Urinary Tract Obstruction (R01)."

Which NIH grant mechanism does this opportunity use?

The mechanism of support is the NIH Research Project Grant (R01), which is generally used for mature, hypothesis-driven projects that can support multi-year research programs.

Is there a related or companion opportunity mentioned?

Yes. NIH notes that this R01 FOA runs in parallel with a separate, scientifically identical FOA using the R21 (exploratory/developmental) mechanism. The intent is to support both earlier-stage, higher-risk concepts (R21) and more fully developed projects (R01) in tandem.

How should applicants think about choosing between the R01 and the companion R21?

Based on the FOA description, projects with strong preliminary data and a well-developed research plan would generally fit the R01 track, while more preliminary, proof-of-concept efforts might be better suited to the R21 companion announcement.

What central problem or gap does the FOA highlight?

The FOA highlights that, despite the significant clinical impact of congenital urinary tract obstruction, the disease mechanisms are not well defined and clinical practice still has persistent disagreements about how best to detect obstruction, predict outcomes, and choose treatments.

What kinds of real-world clinical controversies is NIH trying to address through this research?

The FOA emphasizes controversies that directly affect patient care, including: the actual benefit, risk, and long-term impact of earlier fetal detection and neonatal intervention; uncertainty about the long-term consequences of "watchful waiting" compared with surgical approaches; and the lack of widely accepted consensus on surgical indications and ideal timing of intervention.

Does the FOA support basic research, clinical research, or both?

Both. The scope is intentionally broad and includes basic and clinical research directions, spanning mechanistic discovery through long-term evaluation of treatment strategies.

What research topics or areas of interest are explicitly encouraged?

Areas of interest called out in the FOA include developing objective prognostic markers to help stratify risk and predict progressive kidney damage; investigating genetic determinants of congenital obstructive uropathy; developing reliable animal models that better replicate human congenital obstruction and downstream effects on renal development and fibrosis; and evaluating the long-term effectiveness of various treatment strategies (including comparative studies of surgical techniques, timing strategies, and conservative management) using meaningful outcomes tracked over time.

What is meant by "objective prognostic markers" in the context of this FOA?

Within the FOA context, objective prognostic markers are measurable indicators intended to help clinicians stratify risk and better predict which children are more likely to experience progressive kidney damage and poor kidney outcomes.

Why does the FOA emphasize long-term outcomes and longer-horizon evaluation?

The FOA specifically notes that earlier identification and treatment have not been adequately studied or documented for long-term benefit and risk, and that existing uncertainties often rely on short-term or anecdotal outcomes. The funding opportunity encourages more rigorous evaluation over longer time horizons to clarify what truly improves long-term health.

What types of treatment strategy evaluations does the FOA envision?

The FOA explicitly calls for evaluation of long-term effectiveness of different approaches, which can include comparative studies of surgical techniques, comparisons of timing strategies, assessment of conservative management (including watchful waiting), and tracking kidney function and other meaningful clinical outcomes over time.

Are animal model development and mechanistic studies within scope?

Yes. The FOA highlights a need for reliable animal models that more closely replicate human congenital obstruction and its downstream effects on renal development and fibrosis, supporting mechanistic work and preclinical testing.

Does the FOA include genetics as a research focus?

Yes. The FOA encourages research on genetic determinants of congenital obstructive uropathy, reflecting a need to understand developmental pathways and inherited factors that may influence disease onset, severity, and progression.

Are award amounts and project durations fixed?

No. NIH states that award size and project duration are expected to vary depending on the nature and scope of the proposed research.

How many awards will NIH make under this FOA?

The total number of awards is not fixed. NIH indicates that awards and total dollars committed will depend on typical NIH factors such as the number of applications received, scientific quality, proposed duration, and the strength of the budget justification.

Is cost-sharing or matching required?

No. The FOA states there is no cost-sharing or matching requirement.

Who is eligible to apply?

Eligibility is broad and includes domestic and non-domestic organizations. Eligible applicants include public and state-controlled institutions of higher education; private institutions of higher education; nonprofits (including those with and without 501(c)(3) status, aside from universities); for-profit organizations (other than small businesses); small businesses; and multiple government entities (state, county, city/township, special district, and independent school districts). The FOA also lists federally recognized Native American tribal governments and tribal organizations (other than federally recognized tribal governments), as well as public housing authorities/Indian housing authorities. Foreign institutions are eligible to apply, and eligible federal government agencies may also apply.

Are foreign (non-U.S.) institutions eligible?

Yes. The FOA explicitly states that foreign institutions are eligible to apply.

Are U.S. federal agencies eligible to apply?

Yes. The FOA indicates that eligible federal government agencies may apply.

What type of grant is this administratively?

This is a discretionary grant in the health activity category, administered by the National Institutes of Health (NIH).

When was this opportunity posted, and is it still active?

The opportunity was posted on November 20, 2006. It listed multiple receipt dates and shows a current closing date of September 7, 2009, with an archive date of October 8, 2009. Based on those dates, it is no longer active.

Did this FOA use a single deadline or multiple receipt dates?

It used multiple receipt dates rather than a single one-time deadline.

Where was the full FOA posted?

The full announcement was hosted through the NIH Grants Guide at http://grants.nih.gov/grants/guide/pa-files/PA-07-059.html.

Who should be contacted for access issues with the announcement?

For access issues, NIH directed applicants to contact the NIH Office of Extramural Research (OER) webmaster at FBOWebmaster@OD.NIH.GOV.

What is the overall goal of the FOA in plain terms?

The FOA aims to accelerate progress across the pipeline, from basic mechanisms (including genetics and animal models) to clinical tools (like prognostic markers) to evidence-based comparisons of interventions over time. The end goal is improved prediction, better decisions about timing and type of intervention, and improved long-term outcomes for children at risk of lifelong kidney disease.